208 related articles for article (PubMed ID: 9394741)
21. [What's in the future? New NSAIDs].
Laufer S
Pharm Unserer Zeit; 2002; 31(2):164-9. PubMed ID: 11977452
[No Abstract] [Full Text] [Related]
22. [Prophylaxis of colorectal cancer with non steroidal anti-inflammatory drugs- a new reality?].
Cijevschi C; Rezmireş A; Mintescu E; Stanciu C
Rev Med Chir Soc Med Nat Iasi; 2002; 106(1):35-40. PubMed ID: 12635357
[TBL] [Abstract][Full Text] [Related]
23. Cutting-edge pharmacotherapeutics.
Mege J
Pa Med; 1998 Dec; 101(12):17, 22. PubMed ID: 9883028
[No Abstract] [Full Text] [Related]
24. [Cyclo-oxygenase 2 inhibitors and cancer].
André T; Soria JC
Bull Cancer; 2004 May; 91 Spec No():S59-60. PubMed ID: 15239332
[No Abstract] [Full Text] [Related]
25. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications.
Pascucci RA
J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181
[TBL] [Abstract][Full Text] [Related]
26. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Atkinson HG
Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
[No Abstract] [Full Text] [Related]
27. Celecoxib: a COX-2 inhibitor.
Andrews SA; Wallace CK; Davis RL
Am J Manag Care; 1999 Apr; 5(4):511-8; quiz 522-4. PubMed ID: 10387389
[No Abstract] [Full Text] [Related]
28. Colorectal cancer and non-steroidal anti-inflammatory drugs.
Ota S; Bamba H; Kato A
Acta Pharmacol Sin; 2000 May; 21(5):391-5. PubMed ID: 11324434
[TBL] [Abstract][Full Text] [Related]
29. COX-2 inhibitors--is there cause for concern?
Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P
Nat Med; 1999 Jun; 5(6):621-2. PubMed ID: 10371498
[No Abstract] [Full Text] [Related]
30. Mechanisms underlying chemoprevention of ovarian cancer.
Mills GB
Clin Cancer Res; 2002 Jan; 8(1):7-10. PubMed ID: 11801533
[No Abstract] [Full Text] [Related]
31. COX-2: a molecular target for colorectal cancer prevention.
Brown JR; DuBois RN
J Clin Oncol; 2005 Apr; 23(12):2840-55. PubMed ID: 15837998
[TBL] [Abstract][Full Text] [Related]
32. Cox-2 inhibitors: a new class of medication?
Habershaw TA
Med Health R I; 1999 Sep; 82(9):332-4. PubMed ID: 10517079
[No Abstract] [Full Text] [Related]
33. [The cardiovascular safety of cyclooxygenase-2 (COX-2) inhibitors].
Hasdai D; Gottlieb S; Godbourt U; Hod H; Kaluski E
Harefuah; 2002 Oct; 141(10):922-4. PubMed ID: 12420602
[No Abstract] [Full Text] [Related]
34. COX-2 inhibitors for colorectal cancer.
Elder DJ; Paraskeva C
Nat Med; 1998 Apr; 4(4):392-3. PubMed ID: 9546780
[No Abstract] [Full Text] [Related]
35. [Cyclooxygenase 2 inhibitors and cancer chemoprevention].
Masmoudi A; Chevalier TL; Sabatier L; Soria JC
Bull Cancer; 2004 May; 91 Suppl 2():S77-84. PubMed ID: 15899630
[TBL] [Abstract][Full Text] [Related]
36. [COX-1 and COX-2: functions and pharmacological effects].
Hinz B; Brune K
Pharm Unserer Zeit; 1999 Jan; 28(1):21-9. PubMed ID: 10078026
[No Abstract] [Full Text] [Related]
37. [Rationale and prospects for the use of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancer].
Buecher B; Heymann MF; Blottière HM
Gastroenterol Clin Biol; 2001 Nov; 25(11):967-78. PubMed ID: 11845047
[No Abstract] [Full Text] [Related]
38. [COX-2 inhibitor to whom?].
Martio J
Duodecim; 2000; 116(12):1265-7. PubMed ID: 11988961
[No Abstract] [Full Text] [Related]
39. [Clinical application of cyclooxygenase-2 inhibitors].
Dzielska-Olczak M; Olczak S
Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
[TBL] [Abstract][Full Text] [Related]
40. [New NSAIDS: COX-1, COX-2, what about them?].
Peretz A
Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
